IL-7 Up-Regulates TNF-α-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor

Background Interleukin-7 (IL-7) is a potent regulator of lymphocyte development, which has also significant effects on bone; in fact it is a potent osteoclastogenic factor. Some human solid tumors produce high IL-7 levels, suggesting a potential IL-7 role on tumor development and progression. Methodology We studied 50 male patients affected by solid tumors, and their blood samples were collected at tumor diagnosis. PBMCs were isolated and cultured with/without IL-7 to study its influence on osteoclastogenesis. Serum and cell culture supernatant IL-7 levels were measured by ELISA. The quantitative analysis of IL-7 expression on T and B cells was performed by Real-Time PCR. Principal Findings Serum IL-7 levels were highest in osteolytic cancer patients, followed by cancer patients without bone lesions, and then healthy controls. We showed the IL-7 production in PBMC cultures and particularly in monocyte and B cell co-cultures. A quantitative analysis of IL-7 expression in T and B cells confirmed that B cells had a high IL-7 expression. In all cell culture conditions, IL-7 significantly increased osteoclastogenesis and an anti-IL-7 antibody inhibited it. We demonstrated that IL-7 supports OC formation by inducing the TNF-α production and low RANKL levels, which synergize in promoting osteoclastogenesis. Conclusions We demonstrated the presence of high serum IL-7 levels in patients with bone metastasis, suggesting the use of serum IL-7 level as a clinical marker of disease progression and of bone involvement. Moreover, we showed the capability of IL-7 to stimulate spontaneous osteoclastogenesis of bone metastatic patients and to induce osteoclastogenesis in cancer patients without bone involvement. These findings add further details to the disclosure of the mechanisms controlling bone metastasis in solid tumors.

[1]  Wei-Ping Qian,et al.  IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Pacifici,et al.  Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[4]  P. Appasamy.  Biological and clinical implications of interleukin-7 and lymphopoiesis. , 1999, Cytokines, cellular & molecular therapy.

[5]  J. Szepietowski,et al.  Increased interleukin‐7 levels in the sera of psoriatic patients: lack of correlations with interleukin‐6 levels and disease intensity , 2000, Clinical and experimental dermatology.

[6]  A. Zapata,et al.  Interleukin-7 influences the development of thymic dendritic cells. , 1998, Blood.

[7]  A. Martini,et al.  Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. , 1995, The Journal of rheumatology.

[8]  Wei-Ping Qian,et al.  IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Ikuta,et al.  Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Kalinowski,et al.  Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. , 2003, Endocrinology.

[11]  J. Bijlsma,et al.  Interleukin 7 stimulates tumour necrosis factor α and Th1 cytokine production in joints of patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[12]  J. Haug,et al.  T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  A. Urbano,et al.  Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. , 2002, Cellular signalling.

[14]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[15]  R. Pacifici,et al.  Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. , 2000, Blood.

[16]  L. Zitvogel,et al.  Interleukin‐7 (IL‐7) in Colorectal Cancer: IL‐7 is Produced by Tissues from Colorectal Cancer and Promotes Preferential Expansion of Tumour Infiltrating Lymphocytes , 1997, Scandinavian journal of immunology.

[17]  Levitsky,et al.  Effect of Interleukin‐7 on the In Vitro Development and Maturation of Monocyte Derived Human Dendritic Cells , 2000, Scandinavian journal of immunology.

[18]  B. Seliger,et al.  Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. , 1999, International journal of oncology.

[19]  Chopra,et al.  Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. , 1996, The cancer journal from Scientific American.

[20]  A. Ganser,et al.  In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells. , 1992, Blood.

[21]  J. Haug,et al.  T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand‐Dependent and ‐Independent Mechanisms , 2001 .

[22]  Y. Azuma,et al.  Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts* , 2000, The Journal of Biological Chemistry.

[23]  T. Fry,et al.  Interleukin-7: master regulator of peripheral T-cell homeostasis? , 2001, Trends in immunology.

[24]  B. Żelazowska,et al.  Relationship of serum interleukin‐7 concentration and the coagulation state in children with nephrotic syndrome , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[25]  Robert Krysiak,et al.  Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates , 2005, Journal of cardiovascular pharmacology.

[26]  E. Hannigan,et al.  Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. , 1998, Cancer investigation.

[27]  P. Bernabei,et al.  Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans? , 2006, Bone.

[28]  S. Colucci,et al.  Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  V. Chopra,et al.  Serum levels of interleukins, growth factors and anglogenin in patients with endometrial cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[30]  W. Jiang,et al.  Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. , 2003, Histology and histopathology.

[31]  G. Abraham,et al.  Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Stein,et al.  Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. , 1995, The American journal of pathology.

[33]  G. Watkins,et al.  Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. , 2004, European journal of cancer.

[34]  C. Murphy,et al.  TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. , 2002, Endocrinology.

[35]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[36]  R. Bataille,et al.  Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. , 2002, Blood.

[37]  J. Penninger,et al.  RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.

[38]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[39]  M. Roth,et al.  Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. , 1996, Cancer gene therapy.

[40]  C. Murphy,et al.  TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. , 2002, Endocrinology.

[41]  R. Pacifici,et al.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. , 2002, The Journal of clinical investigation.

[42]  R. Pacifici,et al.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. , 2000, The Journal of clinical investigation.

[43]  P. Appasamy.  Interleukin-7 and lymphopoiesis: biological and clinical implications. , 1995, Cancer treatment and research.